Who: Merck KGaA/Caris Life Sciences
What: Caris’s research division will discover novel targets for use in cancer antibody-drug conjugate products to be developed by Germany’s...
Merck KGaA Looks To Build Cancer ADCs With Caris’s AI Technology
Deal snapshot: The German biopharma will partner with Caris’s research arm to discover and validate novel targets for incorporation into first-in-class antibody-drug conjugates for cancer.
More from Deals
• By
The biopharma sector booked nearly the same number of acquisitions in each of the past two quarters, according to Evaluate data, but there are some encouraging signs in Q2.
• By
Rumor mill suggests a $15bn licensing deal for ivonescimab is in the offing.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.
More from Business
• By
Multi-blockbuster falls short in a giant cell arteritis study.
• By
Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.
• By
The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.